Cargando…
Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were includ...
Autores principales: | Liang, Bo, Gu, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339504/ https://www.ncbi.nlm.nih.gov/pubmed/32631360 http://dx.doi.org/10.1186/s12933-020-01088-3 |
Ejemplares similares
-
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
por: Sharma, Abhinav, et al.
Publicado: (2018) -
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
por: Liang, Bo, et al.
Publicado: (2020) -
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
por: Neves, João Sérgio, et al.
Publicado: (2022) -
Effects of liraglutide on hemodynamic parameters in patients with heart failure
por: Zhang, Jin Ying, et al.
Publicado: (2017) -
Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes
por: Kim, Hae Jin, et al.
Publicado: (2017)